Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

420116 JNK Inhibitor I, (L)-Form, Cell-Permeable - Calbiochem

Overview

Replacement Information

Key Spec Table

Empirical Formula
C₁₆₈H₂₉₃N₆₇O₄₂

Products

Catalogue NumberPackaging Qty/Pack
420116-1MG Plastic ampoule 1 mg
Description
OverviewA cell-permeable, biologically active peptide consisting of a carboxyl terminal sequence derived from the JNK-binding domain (JBD) and an amino terminal peptide containing the HIV-TAT48-57 sequence. Blocks c-Jun NH2-terminal kinase (JNK) signaling by preventing the activation of the transcription factor c-jun (IC50 ~ 1 µM). This effect appears to be due to inhibition of phosphorylation of the activation domains of JNK. Contains the minimal 20-amino acid inhibitory domain of islet-brain (IB) that is shown to be critical for interaction with JNK linked to the 10-amino acid HIV-TAT48-57 sequence as a carrier peptide and two proline residues as spacer. Inhibits IL-1β-induced c-jun and c-fos expression in insulin secreting βTC-3 cells and offers protection against apoptosis. Does not affect insulin secretion and has no effect on either ERK 1/2 or p38 activities.
Catalogue Number420116
Brand Family Calbiochem®
Synonyms(L)-JNKI1, (L)-HIV-TAT₄₈₋₅₇-PP-JBD₂₀, H-GRKKRRQRRRPPRPKRPTTLNLFPQVPRSQDT-NH₂, c-Jun NH₂-terminal kinase, SAPK Inhibitor I
References
ReferencesBarr, R.K., et al. 2002. J. Biol. Chem. 277, 10987.
Bonny, C., et al. 2001. Diabetes 50, 77.
Product Information
ATP CompetitiveN
DeclarationSold under license of U.S. Patents 6,043,083 and 6,410,693.
FormWhite lyophilized solid
FormulationSupplied as a trifluoroacetate salt.
Hill FormulaC₁₆₈H₂₉₃N₆₇O₄₂
Chemical formulaC₁₆₈H₂₉₃N₆₇O₄₂
Hygroscopic Hygroscopic
ReversibleN
Quality LevelMQ100
Applications
ApplicationJNK Inhibitor I, (L)-Form, Cell-Permeable peptide with a C-terminal sequence from the JNK-binding domain and an N-terminal peptide with HIV-TAT48-57 sequence. Blocks c-jun activation (IC50 ~ 1 µM).
Biological Information
Primary TargetJNK
Primary Target IC<sub>50</sub>1 µM
Purity≥97% by HPLC
Physicochemical Information
Cell permeableY
Peptide SequenceH-Gly-Arg-Lys-Lys-Arg-Agr-Gln-Arg-Arg-Arg-Pro-Pro-Arg-Pro-Lys-Arg-Pro-Thr-Thr-Leu-Asn-Leu-Phe-Pro-Gln-Val-Pro-Arg-Ser-Gln-Asp-Thr-NH₂
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage -20°C
Hygroscopic Hygroscopic
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
420116-1MG 04055977187946

Documentation

JNK Inhibitor I, (L)-Form, Cell-Permeable - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

JNK Inhibitor I, (L)-Form, Cell-Permeable - Calbiochem Certificates of Analysis

TitleLot Number
420116

References

Reference overview
Barr, R.K., et al. 2002. J. Biol. Chem. 277, 10987.
Bonny, C., et al. 2001. Diabetes 50, 77.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision24-July-2008 RFH
Synonyms(L)-JNKI1, (L)-HIV-TAT₄₈₋₅₇-PP-JBD₂₀, H-GRKKRRQRRRPPRPKRPTTLNLFPQVPRSQDT-NH₂, c-Jun NH₂-terminal kinase, SAPK Inhibitor I
DescriptionA cell-permeable, biologically active peptide consisting of a carboxyl- terminal sequence derived from the JNK-binding domain (JBD) and an amino-terminal peptide containing the HIV-TAT48-57 sequence that imparts cell-permeability. Blocks the activation domain of c-Jun NH2-terminal kinase (JNK) and prevents the activation of the transcription factor c-Jun (IC50 ~1 µM). Contains the minimal 20-amino acid inhibitory domain of islet-brain (IB), which is critical for interaction with JNK.The peptide is covalently linked to the 10-amino acid HIV-TAT48-57 sequence that acts as a carrier peptide and to two proline residue spacers. Inhibits IL-1β-induced c-Jun and c-fos expression in insulin secreting βTC-3 cells and offers protection against apoptosis. Does not affect insulin secretion and has no significant effect on the activities of ERK1, ERK2, or p38.
FormWhite lyophilized solid
FormulationSupplied as a trifluoroacetate salt.
Intert gas (Yes/No) Packaged under inert gas
Chemical formulaC₁₆₈H₂₉₃N₆₇O₄₂
Peptide SequenceH-Gly-Arg-Lys-Lys-Arg-Agr-Gln-Arg-Arg-Arg-Pro-Pro-Arg-Pro-Lys-Arg-Pro-Thr-Thr-Leu-Asn-Leu-Phe-Pro-Gln-Val-Pro-Arg-Ser-Gln-Asp-Thr-NH₂
Purity≥97% by HPLC
SolubilityH₂O (2 mg/ml)
Storage -20°C
Hygroscopic
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Standard Handling
ReferencesBarr, R.K., et al. 2002. J. Biol. Chem. 277, 10987.
Bonny, C., et al. 2001. Diabetes 50, 77.